Regeneron Pharmaceuticals REGN NASDAQ · Healthcare · United States
$959.41 +4.73% +$43.35
Summary
69 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 29 USD is left as net profit.
- It holds more cash than debt: $3.66B against $2.71B.
- The share price is below the Bulios Fair Price.
- Analysts expect revenue to grow by 31% this fiscal year.
What to watch
- Revenue growth is slowing: 5.6% a year over the last 3 years against 11% over 5 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 20.6 USD for 1 USD of yearly profit. Over the last five years it was 18.0 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 11% a year over 5 years. Over the last 3 years it grew by 5.6% a year. For the next fiscal year analysts expect revenue to grow by 31%. Earnings per share grew by 2.8% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 14 USD
- Research and development 40 USD
- Sales and administration 16 USD
- Taxes and other 1.0 USD
- Net profit 29 USD
Net profit, industry median (Biotechnology) -10 USD
Out of every 100 USD of revenue, 29 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 0.39%
- Paid out of profit
- 7.9%
You receive $3.70 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 34
- Hold 15
- Sell 0
Today's price within the analysts' price targets
The average target of $894.89 is 6.7% below today's price. 69% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Collaboration Revenue 51%
- Product 44%
- Product and Service, Other 4.9%
By region
- UNITED STATES 90%
- Rest Of World 10%
Collaboration Revenue brings in 51% of revenue.
Segments in detail